WikiSWOT.com :: Free Pfizer SWOT Analysis

Pharmaceuticals & Biotech >> Pfizer SWOT Analysis:

Strengths

[list] [*] Industry leaders
[*] Strong sales and marketing infrastructure
[*] Revived blockbuster credentials in recent years - Lyrica, Sutent and Chantix/Champix
[*] Strong R&D departments
[*]R&D innovation with a broad therapeutic coverage
[*]Marketing strength in major geographical and therapeutic areas
[*]Existing Patent protection for a number of years on key products

Weaknesses

case study final exam
[*] Drought in blockbuster launches between
1999 and 2004 (masked by M&A activity)
[*] Entrenchment in low growth therapy area
markets such as CV and CNS
[*] Very limited penetration of biologics market
[*]Discontinuation of products in the latter stages of development
[*]Co-marketing agreements can limit Pfizer's global presence
Stupid

Opportunities

Restructuring strategy designed to cut costs and create a leaner company
Funding available to facilitate product/company
Acquisitions and in-licensing/co- development opportunities
Biologic market expansion
Decreasing development time through favorable R&D collaborations and internal efforts
Emergence of integrated global markets and globalisation for new products
Co-marketing agreements with companies wishing to capitalize on Pfizer's marketing
Strengths, providing Pfizer with strong products and therefore revenue growth

Threats

Considerable exposure to generic competition, focal point of which is Lipitor, due to lose patent exclusivity in 2011
Further large scale M&A activity could further decline Pfizer's profitability
Increased competition for core products like Viagra as its high cost encourages use of cheaper alternative treatments
An increase in the number of safety issues surrounding Viagra
Competition from products similar to Pfizer's in R&D that reach the market close to or before Pfizer's products
The new economic potential of emergent China, India and competition in diverse regional markets.
Economic downturn influencing consumers' purchasing power
Negative publicity
Losing the quality of their drugs and being sued by more consumers.

History: Version 20 (Newest), Version 19, Version 18, Version 17, Version 16, Version 15, Version 14, Version 13, Version 12, Version 11, Version 10, Version 9, Version 8, Version 7, Version 6, Version 5, Version 4, Version 3, Version 2, Version 1 (Oldest)

Go back to the SWOT analysis index, or start a discussion about Pfizer SWOT analysis by adding a comment below WikiSWOT Comments

amy February 22, 2009
does anyone have citations for this info?? thanks!

Name
Email (not shared)
Website

Add comment